Bicycle Therapeutics' Q2 Loss Widens Amid R&D Spend

TL;DR

**BCYC is burning cash fast; expect more dilution or a major partnership to keep the pipeline alive.**

AI Summary

Bicycle Therapeutics PLC reported a net loss of $44.6 million for the three months ended June 30, 2025, a significant increase from the $33.2 million net loss in the prior-year quarter. For the six months ended June 30, 2025, the net loss widened to $89.2 million from $66.5 million in the same period of 2024. The company's cash and cash equivalents decreased to $446.5 million as of June 30, 2025, from $664.9 million as of December 31, 2024, reflecting substantial operational burn. Research and development expenses remain the primary driver of cash utilization, consistent with a clinical-stage biotechnology company. Strategic outlook focuses on advancing its Bicycle® toxin conjugate (BTC) pipeline, with ongoing clinical trials for several oncology candidates. The company continues to rely on its existing cash reserves and potential future collaborations or equity financings to fund operations, as it has no product revenue. A key business change was the issuance of non-voting ordinary shares to Baker Brothers Advisors LP, an affiliated entity, during the six months ended June 30, 2025, indicating continued investor support. The company's ability to continue as a going concern depends on its ability to obtain additional funding.

Why It Matters

Bicycle Therapeutics' widening net loss and significant cash burn are critical for investors, signaling continued reliance on external funding to advance its drug pipeline. This financial trajectory could impact employee morale and future hiring, as well as the company's ability to sustain its research efforts, potentially delaying new treatments for patients. In a competitive biotech landscape, efficient capital deployment is paramount; competitors with stronger financial positions may gain an advantage in drug development and market penetration. The company's ability to secure additional financing or forge lucrative partnerships will dictate its long-term viability and competitive standing.

Risk Assessment

Risk Level: high — The company reported a net loss of $44.6 million for Q2 2025 and a six-month net loss of $89.2 million, alongside a decrease in cash and cash equivalents from $664.9 million to $446.5 million. This substantial cash burn, without any product revenue, indicates a high dependency on future financing, posing significant going concern risks.

Analyst Insight

Investors should closely monitor BCYC's cash runway and upcoming clinical trial milestones. Consider holding if you believe in the long-term potential of their Bicycle® technology and anticipate successful clinical outcomes or strategic partnerships; otherwise, evaluate reducing exposure given the high cash burn and potential for further dilution.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

-$44.6M

eps

N/A

gross Margin

N/A

cash Position

$446.5M

revenue Growth

N/A

Key Numbers

• $44.6M — Net Loss (Q2 2025) (Increased from $33.2M in Q2 2024, indicating widening losses.)
• $89.2M — Net Loss (YTD Q2 2025) (Increased from $66.5M in YTD Q2 2024, showing accelerated losses.)
• $446.5M — Cash & Equivalents (June 30, 2025) (Decreased from $664.9M at Dec 31, 2024, reflecting significant cash burn.)
• 0% — Product Revenue (Company has no product revenue, relying solely on financing and collaborations.)

Key Players & Entities

• BICYCLE THERAPEUTICS PLC (company) — filer of the 10-Q
• Baker Brothers Advisors LP (company) — affiliated entity that received non-voting ordinary shares
• $44.6 million (dollar_amount) — net loss for the three months ended June 30, 2025
• $33.2 million (dollar_amount) — net loss for the three months ended June 30, 2024
• $89.2 million (dollar_amount) — net loss for the six months ended June 30, 2025
• $66.5 million (dollar_amount) — net loss for the six months ended June 30, 2024
• $446.5 million (dollar_amount) — cash and cash equivalents as of June 30, 2025
• $664.9 million (dollar_amount) — cash and cash equivalents as of December 31, 2024
• June 30, 2025 (date) — end of the reporting period
• December 31, 2024 (date) — previous fiscal year-end for cash comparison

FAQ

Risk Factors

• Going Concern Uncertainty [high — financial]: The company has incurred significant net losses, totaling $44.6 million in Q2 2025 and $89.2 million year-to-date. Its cash and cash equivalents decreased to $446.5 million as of June 30, 2025, from $664.9 million at the end of 2024. Bicycle Therapeutics PLC has no product revenue and relies on its existing cash reserves and future financing to fund operations, raising substantial doubt about its ability to continue as a going concern.
• High R&D Expenditure [high — operational]: Research and development expenses are the primary driver of cash utilization, consistent with a clinical-stage biotechnology company. While necessary for pipeline advancement, these costs contribute significantly to the company's net losses and cash burn rate, requiring continuous access to capital.
• Dependence on External Financing [high — financial]: Bicycle Therapeutics PLC has no product revenue and is entirely dependent on external funding sources, such as collaborations or equity financings, to sustain its operations and clinical development programs. The ability to secure future funding is critical for its survival.
• Clinical Trial Risks [medium — regulatory]: The company's strategic outlook relies on advancing its Bicycle® toxin conjugate (BTC) pipeline through clinical trials. These trials carry inherent risks, including potential delays, unexpected adverse events, and failure to demonstrate efficacy or safety, which could impact future development and commercialization.
• Competitive Landscape [medium — market]: The biotechnology sector, particularly in oncology, is highly competitive. Bicycle Therapeutics PLC faces competition from numerous companies developing novel therapies. Success depends on differentiating its BTC platform and achieving clinical milestones ahead of competitors.

Industry Context

The oncology drug development landscape is highly competitive, with significant investment in novel therapeutic modalities. Companies like Bicycle Therapeutics PLC are focused on innovative approaches, such as antibody-drug conjugates and peptide-drug conjugates, to target cancer cells more effectively. The industry is characterized by long development cycles, high R&D costs, and stringent regulatory requirements.

Regulatory Implications

As a clinical-stage biotechnology company, Bicycle Therapeutics PLC is subject to rigorous oversight by regulatory bodies like the FDA. Successful progression through clinical trials (Phase 1, 2, 3) is essential for eventual market approval. Any delays, safety concerns, or failure to meet efficacy endpoints in ongoing trials for its BTC pipeline could have significant negative implications for its future.

What Investors Should Do

1. Monitor cash runway and future financing activities.
2. Evaluate clinical trial progress and data readouts.
3. Assess competitive positioning within the oncology market.

Key Dates

• 2025-06-30: End of Q2 2025 — Reported net loss of $44.6 million and cash and cash equivalents of $446.5 million. This marks a significant increase in losses and a substantial decrease in cash from the prior year and year-end 2024.
• 2025-01-01: Start of 2025 fiscal year — The six-month period ending June 30, 2025, saw a net loss of $89.2 million, indicating accelerated losses compared to the same period in 2024.
• 2025-06-30: Issuance of non-voting ordinary shares to Baker Brothers Advisors LP — This event, occurring within the first six months of 2025, indicates continued investor support from an affiliated entity, despite the company's financial challenges.
• 2024-12-31: End of Fiscal Year 2024 — Cash and cash equivalents stood at $664.9 million, providing a baseline for the significant cash burn observed in the first half of 2025.
• 2024-05-23: Investors Purchase Agreement — Indicates a prior financing event that provided capital, highlighting the company's history of relying on external funding.

Glossary

Bicycle® toxin conjugate (BTC)

A proprietary therapeutic modality developed by Bicycle Therapeutics that utilizes small, bicyclic peptides to deliver payloads, such as toxins, to target cells, primarily in oncology. (This is the core technology platform the company is focused on advancing through its clinical pipeline.)

Going Concern

An accounting principle that assumes a company will continue to operate for the foreseeable future. If there is substantial doubt about a company's ability to continue as a going concern, it must be disclosed. (The company's financial situation raises substantial doubt about its ability to continue as a going concern, highlighting its reliance on future funding.)

Net Loss

The total expenses of a company exceed its total revenues over a specific period, resulting in a negative profit. (Bicycle Therapeutics PLC has consistently reported significant net losses, a common characteristic of clinical-stage biotechnology companies investing heavily in R&D.)

Cash Burn Rate

The rate at which a company spends its cash reserves, typically used for companies that are not yet profitable. (Understanding the cash burn rate is crucial for assessing how long the company can operate before needing additional financing.)

Year-Over-Year Comparison

Compared to the prior year, Bicycle Therapeutics PLC has seen a significant increase in net losses, with Q2 2025 losses at $44.6 million versus $33.2 million in Q2 2024, and year-to-date losses widening to $89.2 million from $66.5 million. This accelerated loss is accompanied by a substantial decrease in cash and cash equivalents, falling to $446.5 million from $664.9 million at the end of 2024, underscoring a higher operational burn rate. While no new product revenue has been generated, the company has continued to secure investor support through equity issuances, such as the non-voting shares issued to Baker Brothers Advisors LP.

Filing Documents

• bcyc-20250630x10q.htm (10-Q) — 2393KB
• bcyc-20250630xex10d1.htm (EX-10.1) — 349KB
• bcyc-20250630xex10d2.htm (EX-10.2) — 35KB
• bcyc-20250630xex10d3.htm (EX-10.3) — 6KB
• bcyc-20250630xex31d1.htm (EX-31.1) — 14KB
• bcyc-20250630xex31d2.htm (EX-31.2) — 14KB
• bcyc-20250630xex32d1.htm (EX-32.1) — 10KB
• bcyc-20250630xex10d2001.jpg (GRAPHIC) — 1KB
• 0001558370-25-010843.txt ( ) — 9799KB
• bcyc-20250630.xsd (EX-101.SCH) — 63KB
• bcyc-20250630_cal.xml (EX-101.CAL) — 57KB
• bcyc-20250630_def.xml (EX-101.DEF) — 286KB
• bcyc-20250630_lab.xml (EX-101.LAB) — 544KB
• bcyc-20250630_pre.xml (EX-101.PRE) — 429KB
• bcyc-20250630x10q_htm.xml (XML) — 1563KB

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION 1 Item 1.

Financial Statements (unaudited)

Financial Statements (unaudited) 1 Condensed Consolidated Balance Sheets 1 Condensed Consolidated Statements of Operations and Comprehensive Loss 2 Condensed Consolidated Statements of Shareholders' Equity 3 Condensed Consolidated Statements of Cash Flows 4 Notes to Condensed Consolidated Financial Statements 5 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 24 Item 3. Quantitative and Qualitative Disclosure About Market Risk 39 Item 4.

Controls and Procedures

Controls and Procedures 39

- OTHER INFORMATION

PART II - OTHER INFORMATION 40 Item 1.

Legal Proceedings

Legal Proceedings 40 Item 1A .

Risk Factors

Risk Factors 40 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 98 Item 3. Defaults Upon Senior Securities 99 Item 4. Mine Safety Disclosures 99 Item 5. Other Information 99 Item 6. Exhibits 100

SIGNATURES

SIGNATURES i Table of Contents SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS This Quarterly Report on Form 10-Q, or this Quarterly Report, contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. These statements may be identified by such forward-looking terminology as "will," "may," "should," "expects," "intends," "plans," "anticipates," "believes," "estimates," "predicts," "potential," "continue" or variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Any forward-looking statement involves known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statement. Forward-looking statements include statements, other than statements of historical fact, about, among other things: the initiation, timing, progress and results of our preclinical studies and clinical trials, and our research and development programs; our ability to advance our product candidates into, and successfully complete, clinical trials; our reliance on the success of product candidates in our pipeline programs for our Bicycle Drug Conjugate, or BDC molecules, Bicycle Tumor-Targeted Immune Cell Agonist , or Bicycle TICA molecules, and Bicycle Radioconjugates, or BRC molecules, as well as our other pipeline programs; our ability to utilize our screening platform to identify and advance additional product candidates into clinical development; the timing or likelihood of regulatory filings and approvals; the commercialization of our product candidates, if

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements . Bicycle Therapeutics plc Condensed Consolidated Balance Sheets (In thousands, except share and per share data) (Unaudited) June 30, December 31, 2025 2024 Assets Current assets: Cash and cash equivalents $ 721,451 $ 879,520 Prepaid expenses and other current assets 22,058 13,432 Research and development incentives receivable 60,753 35,653 Total current assets 804,262 928,605 Property and equipment, net 8,307 9,516 Operating lease right-of-use assets 5,806 7,673 Other assets 13,809 11,074 Total assets $ 832,184 $ 956,868 Liabilities and shareholders' equity Current liabilities: Accounts payable $ 18,263 $ 15,793 Accrued expenses and other current liabilities 44,538 41,246 Deferred revenue, current portion 14,621 10,191 Total current liabilities 77,422 67,230 Operating lease liabilities, net of current portion 1,765 3,990 Deferred revenue, net of current portion 82,943 91,467 Other longterm liabilities 1,139 1,121 Total liabilities 163,269 163,808 Commitments and contingencies (Note 11) Shareholders' equity: Ordinary shares, including non-voting ordinary shares, 0.01 nominal value; 159,802,729 and 155,876,645 shares authorized on June 30, 2025 and December 31, 2024, respectively; 69,253,944 and 69,061,418 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively 893 890 Additional paid-in capital 1,491,882 1,472,842 Accumulated other comprehensive (loss) income ( 3,363 ) 119 Accumulated deficit ( 820,497 ) ( 680,791 ) Total shareholders' equity 668,915 793,060 Total liabilities and shareholders' equity $ 832,184 $ 956,868 The accompanying notes are an integral part of the condensed consolidated financial statements 1 Table of Contents Bicycle Therapeutics plc Condensed Consolidated Statements of Operations and Comprehensive Loss (In thousands, except share and per sh

View Full Filing

View this 10-Q filing on SEC EDGAR